A firm based in California with additional offices throughout the USA and Asia invests broadly in the healthcare and technology sectors, in both venture and growth-stage financing rounds. The firm has a large fund that invests only in rounds that raise $10 million or more. The firm makes investments globally.

Within healthcare, the firm focuses on biopharma, and also invests in medical devices, healthcare IT and healthcare service providers. The firm is not currently seeking opportunities in diagnostics. In biopharma, the firm prefers to invest in companies that have obtained data from human clinical trials; however, the firm also invests in breakthrough therapeutic technologies at the preclinical stage. In medical devices, the firm only invests in growth-stage companies with an approved product and initial revenues; the firm prefers to invest in breakthrough device technologies and avoids commodity markets. The firm has a broad portfolio and is open to any indication area, but has a particular focus in oncology and orphan diseases, and typically does not invest in infectious diseases.

Within the service provision and IT sectors, the firm is focused on opportunities that provide cost savings to the healthcare system; in this sector, the firm’s expertise is primarily in companies that target healthcare providers as customers, but the firm is also open to considering other areas of the services/IT space. The firm has no fixed requirements for companies or management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment fund offers business training programs for early stage ventures solving global challenges within several fields, including healthcare. The firm typically works with companies who have received less than $1 million in institutional funding and are looking to raise $500K or more in the next 12-18 months. In each program, 12innovative ventures are selected to participate, and among them, two will receive $50,000 investment each through a peer-selection process. The US-based programs are open to companies that are US-based, serving the US market, or with presence in the US.

Within healthcare, the firm is interested in entrepreneurs with solutions that will increase and/or improve access to both healthcare and treatment for low-wealth individuals. Examples may include healthcare IT solutions or innovative medtech and diagnostic tools. The program seeks companies that have developed some sort of traction, either revenue-based or meaningful customer feedback, user acquisition, successful pilots, or strategic partnerships.

The firm looks at experience, competency, and the overall dynamic of management teams. To participate in the business-training programs, the company must have at least one full time team member.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity firm based in Shanghai, China, provides growth/expansion capital to companies with validated business models, with investments typically ranging from $10M-$100M. Investments are made into mature companies ready for an IPO within 12-18 months or earlier-stage companies with platform technologies or a broad portfolio of assets, especially therapeutics/devices/technologies that would be applicable to the Asian market. Minority or majority equity investments are made in selected companies.

As for earlier-stage companies, the firm is opportunistic in terms of sector and is open to therapeutics, medical devices and healthcare IT companies, but prefers to invest in companies with products on the market. Companies with a platform technology capable of generating several assets or a broad portfolio targeting different indications are more likely to be considered. Software-based or other Health IT oriented companies should have considerable traction, proving that their business model is viable. One of the firm’s past investments includes a biologic’s CMO.

The firm invest in companies based in the U.S. or China, and requires companies that have a proven business model, as they provide expansion capital and access to an extensive network of advisors, industry executives and business relationships to provide portfolio companies support from financial and strategic angels. Board representation is typically required along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A healthcare focused venture capital firm based in New York City was formed by accomplished retinal surgeons and a team of investment professionals that have partnered to address the need for funding early stage ophthalmic focused companies. The firm is currently raising its first fund, and is currently allocating up to $750,000 utilizing convertible notes in seed stage companies and equity in post seed stage companies. The firm is interested in co-investing as part of a syndicate. The firm is currently seeking new opportunities based in North America and Europe.

The firm specializes in early-stage investments in innovative ophthalmic diagnostic and treatment solutions. The firm seeks to invest in a broad range of technologies applicable to ophthalmology, including small molecule and biologic therapeutics, low- and high-risk medical devices, diagnostics, drug delivery, and software solutions. The firm would also consider generic drugs but with less interest. The firm considers companies at all stages, but prefers early stage projects with some clinical or other supporting data where it can add meaningful expertise outside of financial capital.

The firm seeks management teams formed by experienced entrepreneurs with track records of success and scientists with domain expertise in their field. The firm opportunistically seeks board seats on a deal-by-deal basis particularly in situations where they can add meaningful value.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A strategic investment company formed by a pharma firm makes investments ranging from $3 million to $20 million acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and has filed (or will file) a US IND.

The firm invests in therapeutics, and in this sector the firm is interested in both early stage, preclinical assets and companies with assets in the clinic. The firm will consider any type of therapeutic technology (including small molecules, large molecules and gene therapies), and has a strong preference for investing in orphan drugs and other niche disease areas. It is preferred that indications have validated clinical endpoints and can be studied using small trials. Indications that require large clinical trials, including as cardiovascular diseases, CNS diseases and primary care indications (such as influenza) will not be considered. Drug-device combinations will also be considered.

The firm prefers to work with companies who have opened dialogue with the FDA. The firm considers a high-quality management team to be a significant requirement of their investment criteria. It is preferred that assets can reach the marketplace 3-5 years post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Life Science focused private equity and venture capital firm affiliated with a sovereign wealth fund invests in companies at all stages, from early stage seeking venture capital to late stage companies seeking growth and expansion capital. Typically, the firm invests USD 5-15 million per opportunity. The firm can invest globally and is actively seeking new investment opportunities.

The firm seeks to invest in breakthrough healthcare biotech, medical devices, diagnostics, healthcare IT, and biorenewable and bioindustrial technologies. The firm is open to a wide range of technologies including novel techniques such as stem cells and genomics, and will consider investing in any area of medicine. The firm prefers to invest in technologies that have attained clinical validation.

The firm seeks a strong and experienced management team. The firm may take a board seat on a case by case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm founded in 2002 invests solely in life sciences companies and is currently investing from a US$35M private fund and a $50M government matching fund. Equity allocation size varies and can reach up to US$3M per deal. The firm is open to leading or co-investing. The firm focuses 70% on Asia and 30% on global deals and is currently seeking new opportunities.

Within life sciences, the firm is most interested in biotech therapeutics including biologics, small molecules, and drug formation. The firm considers all indications with a focus on neurodegeneration and psychology. The firm prefers assets ranging from preclinical to phase II. Historically the firm has invested in medical technology, agricultural biotech, and biotech R&D services, but will consider these sectors with less interest.

The firm is looking for experienced management teams with strong sector expertise. For domestic deals, the firm seeks an active role in its portfolio companies and would require a board seat on a case-by-case basis. For foreign deals, the firm prefers to syndicate with a strong lead that can work with investee companies closely.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com